A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Autor: Cho, Byoung Chul, Han, Ji-Youn, Kim, Sang-We, Lee, Ki Hyeong, Cho, Eun Kyung, Lee, Yun-Gyoo, Kim, Dong-Wan, Kim, Joo-Hang, Lee, Gyeong-Won, Lee, Jong-Seok, Shim, Byoung Yong, Kim, Jin-Soo, Chun, Sang Hoon, Lee, Sung Sook, Kim, Hye Ryun, Hong, Min Hee, Ahn, Jin Seok, Sun, Jong-Mu, Lee, Youngjoo, Lee, Dae Ho, Kang, Ji Ah, Lee, NaMi, Kwon, Mi-Jung, Espenschied, Carin, Yablonovitch, Arielle, Ahn, Myung-Ju
Zdroj: In Journal of Thoracic Oncology April 2022 17(4):558-567
Databáze: ScienceDirect